{
  "slug": "blood-clot-long-haul-flight",
  "question": "What are the odds of a serious blood clot after a long-haul flight?",
  "category": "transport",
  "tags": [
    "travel"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Blood clots from flying occupy a reliable slot in the pre-trip anxiety rotation, somewhere between deep-vein dread and the impulse to buy compression stockings at the airport pharmacy. The fear is specific enough to drive a small consumer market — flight socks, aspirin before boarding, aisle-seat upgrades “so I can walk around” — yet most travelers would struggle to put a number on the actual risk. The intuitive sense is that it is meaningfully dangerous, probably somewhere around 1 in 100 to 1 in 500 per long flight, which overshoots the epidemiology by one to two orders of magnitude.\n",
    "rough_estimate": "most travelers guess somewhere in the 1-in-100 to 1-in-500 range per long flight",
    "kind": "intuition"
  },
  "native": {
    "display": "~1 in 4,656 per long-haul flight (>4 h)",
    "numerator": 1,
    "denominator": 4656,
    "unit": "per long-haul flight",
    "population": "employees of international organisations taking flights >4 hours (Kuipers et al. cohort)"
  },
  "normalized": {
    "lifetime_us_adult": 0.000215,
    "display": "~1 in 4,656 per long-haul flight",
    "log_value": -3.67,
    "assumptions": "The headline figure comes directly from Kuipers et al. (2007): one symptomatic VTE event per 4,656 long-haul flights (>4 hours) in a cohort of 8,755 employees of international organisations followed for six years. This is an absolute incidence figure for a single flight, not a lifetime accumulation, so normalized.lifetime_us_adult here represents the per-flight probability (~0.0215%) rather than a conventional US-adult lifetime figure. The scope is set to activity_specific_lifetime accordingly. The Chandra et al. (2009) meta-analysis found a pooled relative risk of 2.0 (95% CI 1.5–2.7) for VTE in travelers vs non-travelers, with a 26% increase per additional 2 hours of air travel, consistent with the Kuipers absolute rate. Fatal pulmonary embolism from a single long-haul flight is estimated at roughly 1 in 1,000,000 based on the observation that PE accounts for roughly 10–20% of VTE events and case fatality for PE in otherwise healthy travelers is low.\n",
    "uncertainty": {
      "low": 0.0001,
      "high": 0.0005
    },
    "scope": "activity_specific_lifetime"
  },
  "sources": [
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/17896862/",
      "title": "The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations",
      "publisher": "PLoS Medicine (Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR)",
      "source_type": "peer_reviewed",
      "statistic": "One VTE event per 4,656 long-haul flights; incidence rate 3.2/1,000 person-years after long-haul flights vs 1.0/1,000 person-years in unexposed periods; risk ratio 3.2 (95% CI 1.8-5.6)",
      "excerpt": "\"Incidence rate of 3.2/1,000 PY after long-haul flights versus 1.0/1,000 PY in individuals not exposed. One event per 4,656 long-haul flights.\"\n",
      "source_date": "2007-09-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413163839/https://pubmed.ncbi.nlm.nih.gov/17896862/",
      "calculation_notes": "Kuipers tracked 8,755 employees of international organisations (UN system, World Bank, etc.) from 2000-2005, accumulating 6,872 person-years of long-haul-flight-exposed time. 22 VTE events occurred within 8 weeks of a long-haul flight. The “1 per 4,656 flights” figure is the primary absolute risk estimate and maps directly to our native value. The cohort is younger and healthier than the general population (employed, medically cleared for international travel), so this may slightly underestimate risk for the general flying public but is the best prospective absolute risk figure available.\n",
      "independence_note": "Kuipers is the primary prospective cohort study on flight-associated VTE. Fully independent of the Chandra meta-analysis (which pooled other studies but not Kuipers itself) and of CDC's secondary guidance; shares Leiden-group co-authors with the Cannegieter MEGA case-control study referenced in the personal-factor multipliers, so treat the two Leiden-pipeline estimates as methodologically linked.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/19581633/",
      "title": "Meta-analysis: travel and risk for venous thromboembolism",
      "publisher": "Annals of Internal Medicine (Chandra D, Parisini E, Mozaffarian D)",
      "source_type": "peer_reviewed",
      "statistic": "Pooled relative risk for VTE in travelers 2.0 (95% CI 1.5-2.7); 26% higher risk for every 2 hours of air travel; 18% higher risk per 2-hour increase in travel by any mode",
      "excerpt": "\"Overall pooled relative risk for VTE in travelers was 2.0 (95% CI, 1.5 to 2.7). 26% higher risk for every 2 hours of air travel.\"\n",
      "source_date": "2009-08-04",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413163915/https://pubmed.ncbi.nlm.nih.gov/19581633/",
      "calculation_notes": "Chandra et al. pooled 14 studies (4,055 VTE cases). The 2.0 relative risk is for any travel >4 hours vs no travel; when corrected for selection bias in control groups, the estimate rises to 2.8 (CI 2.2–3.7). The dose-response gradient (26% per 2h of air travel) supports the biological plausibility of the Kuipers absolute risk figure and anchors the “risk rises with duration” framing. This is a relative risk, not an absolute risk; combined with background VTE incidence of ~1–2 per 1,000 person-years, it is consistent with the Kuipers 1-in-4,656-flights figure.\n",
      "independence_note": "Chandra et al. meta-analysis includes the Cannegieter MEGA study data but not the Kuipers cohort study (published in the same year). The two primary sources here are therefore largely independent on the population data, though they share co-authors from the Leiden group.\n"
    },
    {
      "url": "https://www.cdc.gov/blood-clots/risk-factors/travel.html",
      "title": "Understanding Your Risk for Blood Clots with Travel",
      "publisher": "US Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "More than 300 million people travel on long-distance flights each year; risk of developing a blood clot is generally very small; most people who develop travel-associated blood clots have one or more other risk factors",
      "excerpt": "\"Even if you travel a long distance, the risk of developing a blood clot is generally very small. Most people who develop travel-associated blood clots have one or more other risks for blood clots.\"\n",
      "source_date": "2024-05-14",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413163957/https://www.cdc.gov/blood-clots/risk-factors/travel.html",
      "calculation_notes": "CDC does not publish a specific per-flight incidence figure but corroborates the “generally very small” framing and confirms that the risk-factor-dependent subgroup story is the dominant clinical concern. The 300-million-flights-per-year denominator is useful context for the absolute risk figure from Kuipers. Used as authoritative corroboration, not as the primary quantitative source.\n",
      "independence_note": "CDC guidance is editorially independent of the Leiden group studies but cites the same underlying literature base.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Death in a commercial plane crash (per flight)",
      "lifetime_us_adult": 7.3e-8
    },
    {
      "label": "Fatal PE from a single long-haul flight (estimated)",
      "lifetime_us_adult": 0.000001
    },
    {
      "label": "Dengue per 2-week trip to endemic area",
      "lifetime_us_adult": 0.005
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Oral contraceptive use + long-haul flight",
      "multiplier": 14,
      "notes": "The Cannegieter MEGA study (2006) found an estimated OR >20 for OCP users who traveled >4 hours; conservative multiplier of ~14x applied to the baseline risk. This is the single largest identified risk factor interaction."
    },
    {
      "factor": "Obesity (BMI >30)",
      "multiplier": 5,
      "notes": "MEGA study: OR 9.9 (95% CI 3.6-27.6) for obese travelers vs lean non-travelers; ~5x above the travel-only baseline after accounting for the baseline travel OR of 2.1."
    },
    {
      "factor": "Factor V Leiden carrier",
      "multiplier": 4,
      "notes": "MEGA study: OR 8.1 (95% CI 2.7-24.7) for FVL carriers who traveled by car/bus/train; similar magnitude expected for air travel."
    },
    {
      "factor": "Flight duration >8 hours (vs 4-6 hours)",
      "multiplier": 2,
      "notes": "Chandra meta-analysis: 26% higher VTE risk per additional 2 hours of air travel; an 8-hour flight vs a 4-hour flight implies roughly 2x the risk."
    },
    {
      "factor": "Recent surgery or immobilisation (within 4 weeks)",
      "multiplier": 5,
      "notes": "CDC lists recent surgery/injury within 3 months as a major risk factor; interaction with prolonged immobility during flight compounds the risk substantially."
    }
  ],
  "short_label": "Blood clot (flight)",
  "myth_framing": "overrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "acute",
  "outcome_type": "recoverable_injury",
  "valence": "negative",
  "caveats": "The headline ~1-in-5,000 figure represents any symptomatic venous thromboembolism (DVT or PE) within 8 weeks of a single long-haul flight (>4 hours), not death. Most events are deep vein thrombosis, which is treatable and rarely fatal. Pulmonary embolism, the dangerous complication, accounts for a minority of these events and is estimated at roughly 1 in 20,000–50,000 per flight; fatal PE at roughly 1 in 1,000,000 per flight. The Kuipers cohort consists of employees of international organisations who are younger and healthier than the general population, which may underestimate risk for older or less healthy travelers. Conversely, this population flies frequently, and the study found that multiple flights in short timeframes elevate risk further. The personal factor multipliers are drawn from the Cannegieter MEGA case-control study and represent odds ratios for the combined exposure (travel + factor), not clean multiplicative interactions; they are order-of-magnitude guides, not precise adjustments. Current clinical guidelines (ACCP, NICE) do not recommend aspirin prophylaxis for air travel; graduated compression stockings are supported for high-risk travelers only.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 5,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.75,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single stylized airplane seat in muted blue-grey tones against a pale background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/blood-clot-long-haul-flight"
}